34540198|t|Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.
34540198|a|AIMS: To review recent data and relevant of the role of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin lymphoma (NHL). METHODS: Review and compilation of the most recent and relevant data published in full text and abstract forms of anti-CD19 CAR T-cell therapy for B-cell NHL. RESULTS: Different anti-CD19 CAR T-cell therapy products have been tested and shown significant clinical activity across B-cell NHL patients. The objective responses in relapsed DLBCL, FL and MCL were 50-83%, 83-93% and 93%, respectively. CONCLUSIONS: Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.
34540198	5	9	CD19	Gene	930
34540198	10	35	chimeric antigen receptor	Gene	9970
34540198	54	70	B-cell lymphomas	Disease	MESH:D016393
34540198	171	175	CD19	Gene	930
34540198	176	201	chimeric antigen receptor	Gene	9970
34540198	203	206	CAR	Gene	9970
34540198	227	254	B-cell non-Hodgkin lymphoma	Disease	MESH:D016393
34540198	256	259	NHL	Disease	MESH:D008228
34540198	381	385	CD19	Gene	930
34540198	386	389	CAR	Gene	9970
34540198	409	419	B-cell NHL	Disease	MESH:D016393
34540198	445	449	CD19	Gene	930
34540198	450	453	CAR	Gene	9970
34540198	542	552	B-cell NHL	Disease	MESH:D016393
34540198	553	561	patients	Species	9606
34540198	599	604	DLBCL	Disease	
34540198	606	608	FL	Disease	
34540198	613	616	MCL	Disease	MESH:C535516
34540198	678	682	CD19	Gene	930
34540198	683	686	CAR	Gene	9970
34540198	746	757	B-cell NHLs	Disease	MESH:D015448
34540198	Negative_Correlation	MESH:D016393	9970
34540198	Association	MESH:D015448	9970
34540198	Association	MESH:D015448	930
34540198	Association	MESH:D016393	930

